Loading…
← CockpitCompetitor Analysis › ENSG Ensign Group, Inc.Open in the cockpit ↗

Ensign Group, Inc.ENSGCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Operator of skilled nursing, senior living and rehabilitation facilities across the US, run under a decentralized local-operator model.

Momentum strong 66
Mkt cap
$10.7B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$72.2M
20-day average traded
Fwd P/E
21.3×
forward earnings
ROIC−WACC
+1.2 pp
WACC 7.9%
Hurdle
-4 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · USD$182.98
1D-1.6%
1W-1.7%
1M+4.0%
3M+1.7%
6M+2.6%
YTD+5.0%
1Y+3.0%
ATR %2.5%
Beta0.02
52w lowhigh16.1% off high

What Ensign does

Operator of skilled nursing, senior living and rehabilitation facilities across the US, run under a decentralized local-operator model.

Operates each facility as a largely independent local business, with local leaders given autonomy and a share in results, and earns mostly from regulated Medicare and Medicaid payments per patient day. It improves facilities it buys by lifting quality and occupancy. It spun off CareTrust REIT in 2014 and Pennant Group, home health and hospice, in 2019.

Products and services

  • Skilled nursing facilities
  • Senior living/assisted living
  • Home health/hospice

Customers

  • Medicare/Medicaid patients
  • Seniors needing skilled nursing or assisted living

Where it sits in the supply chain

  • Healthcare
  • Post-acute/senior care services
  • Skilled nursing and senior living…

What could go right

  • Aging population driving skilled-nursing demand
  • Accretive facility acquisitions

What could go wrong

  • Heavy Medicaid/Medicare reimbursement dependence
  • Staffing cost inflation/shortages

Moat: narrow (scale, process know-how, distribution). Proven decentralized operating/acquisition model that consistently improves underperforming facilities it acquires.

Headquarters: San Juan Capistrano, California, USA · Founded: 1999 · Employees: 46,000

Named competitors

Ensign at a glance

Size Ensign (ENSG) is a United States Health Care company (Medical/Nursing Services) with a market value of $10.7B, the 740th largest of 3,085 United States companies the cockpit tracks. Shares closed at $182.98 on 18 Nov 2026.

Performance Over six months the shares gained 2.6%, against +16.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue grew 17.5% over the last twelve months (peer median +9.4%); the operating margin is 9.0% (peer median 9.8%).

Valuation It trades at 21.3× forward earnings against a peer median of 20.1× (9th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.2 points above its cost of capital (7.9% WACC).

Short interest Short interest is 2.5% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 118ENSG 107
Six months, rebased to 100: Ensign against the median of its 19 peers (local-currency closes).

Ensign financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.67B$5.06B$4.26B$3.66B$2.94B
Revenue growth—+19%+16%+24%—
Gross profit$820M$695M$585M$454M$374M
EBITDA$632M$538M$445M$264M$277M
Net income$399M$344M$298M$209M$225M
Free cash flow$510M$371M$189M$270M$182M
Capital expenditure$186M$194M$158M$106M$87.5M
Total debt$2.29B$2.21B$1.97B$1.87B$1.57B

Quarterly statements and history in the cockpit →

Ensign competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-40%-20%0%+20%DVAFME300015EHCBTSGSOLVSHLRDNTCONLFSTOPCHBLLNHIMSPHIAMCOV-BLHLALPATHLABACHCENSG6-month return →1-month return →
Up and to the right = strong over both horizons. Ensign is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×DVAFME300015EHCBTSGSOLVSHLRDNTLFSTBLLNPHIAMCOV-BLALPATHLABENSGRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ensign is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%DVAFME300015EHCBTSGSHLRDNTLFSTOPCH3774BLLNMCOV-BLHLALPATHLABENSGGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ensign is the large dot.

Ensign competitors and peer comparison

Head to head with its named competitors (ENSG vs NHC vs BKD vs PACS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ensign ENSG$10.7B+3%+17%9%21.3×12.7%
National HealthCare NHC$3.16B+1%+6%0%n/a6.4%
Brookdale Senior Living BKD$2.06B-36%-8%6%482.6×19.3%
PACS PACS$7.35B+25%+11%8%17.5×7.5%
Pennant PNTG$1.26B+1%+39%6%23.7×20.7%
Sonida Senior Living SNDA$1.59B-11%+70%-8%n/an/a

How Ensign compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ensign against its 19 peers (data as of 18 Nov 2026)
MeasureENSGPeer medianRank in peer set
1-month return+4.0%+7.2%9th lowest of 20
6-month return+2.6%+16.9%4th lowest of 19
Distance from 52-week high-16.1%-9.0%7th lowest of 20
Revenue growth (TTM)+17.5%+9.4%7th highest of 20
Operating margin9.0%9.8%8th lowest of 20
Forward P/E21.3×20.1×9th most expensive of 18
Growth the price implies (Req g, 7 yrs)12.7%13.2%9th least demanding of 17
Growth delivered (Del g)+16.5%+12.5%6th highest of 17
Hurdle (Req g minus delivered)-3.7 pp+1.8 pp6th least demanding of 17
ROIC minus cost of capital+1.2 pp+0.5 pp9th highest of 20
EV / EBITDA19.9×13.9×5th most expensive of 16
Net debt / EBITDA3.0×2.7×8th most indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ensign ENSGUnited States$10.7B+3%+17%9%21.3×12.7%+16.5%
DaVita DVAUnited States$10.2B-18%+6%15%10.1×-2.5%+3.4%
Fresenius Medical Care FME.DEGermany$11.2B+3%-1%11%9.5×-4.8%+1.9%
Aier Eye Hospital 300015.SZChina$12.5B-14%+5%21%30.1×11.8%+13.4%
Encompass Health EHCUnited States$13.2B+27%+9%18%20.1×5.7%+5.0%
BrightSpring Health Services BTSGUnited States$13.6B+17%+23%4%28.8×24.9%+18.3%
Solventum SOLVUnited States$14.7B+14%-3%8%11.7×n/an/a
Sonic Healthcare SHL.AXAustralia$6.87B+6%+14%9%17.4×9.1%+3.5%
RadNet RDNTUnited States$5.66B+32%+21%5%93.2×38.8%+13.7%
Concentra Group Holdings Parent CONUnited States$5.31B+65%+12%17%22.3×3.6%+7.9%
Lifestance Health LFSTUnited States$5.24B+79%+23%6%51.8×33.4%+30.4%
Option Care Health OPCHUnited States$4.75B+43%+4%6%15.7×2.0%+13.2%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%n/a57.4%+48.4%
BillionToOne BLLNUnited States$4.37B+7%+72%10%115.3×22.8%+71.9%
Hims & Hers Health HIMSUnited States$4.00B-26%+30%-1%n/an/an/a
Koninklijke Philips PHIA.ASNetherlands$29.0B+17%-1%10%16.4×5.9%+0.6%
Medicover MCOV-B.STSweden$3.87B+21%+3%7%36.1×19.6%+20.2%
Labcorp LHUnited States$30.1B+44%+6%11%19.3×14.5%0.0%
Dr. Lal PathLabs LALPATHLAB.NSIndia$3.53B+15%+17%24%50.5×32.3%+11.8%
Acadia Healthcare ACHCUnited States$3.49B+56%+4%10%18.6×n/an/a

Questions

Who are Ensign's main competitors?
Named competitors: National HealthCare Corporation (NHC), Brookdale Senior Living (BKD), PACS Group (PACS), Pennant Group (PNTG), Sonida Senior Living (SNDA). The cockpit's measured peer set (industry) also includes DaVita (DVA), Fresenius Medical Care (FME.DE), Aier Eye Hospital (300015.SZ), Encompass Health (EHC), BrightSpring Health Services (BTSG), Solventum (SOLV).
Is Ensign expensive compared with its peers?
On forward p/e it trades at 21.3× against a peer median of 20.1×, 9th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Ensign stock performed?
Over six months to 18 Nov 2026 the shares returned +2.6% against +16.9% for the median peer; over one year +3.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.